INTRODUCTION
============

Intensive lifestyle interventions (eg, promoting increased physical activity and weight loss) can be effective in decreasing the incidence of type 2 diabetes mellitus (T2DM).^[@r01]^ However, healthcare resources are limited, and participants in interventions to prevent diabetes should be prioritized. Identification of individuals at high risk of T2DM could facilitate the targeting of prevention efforts to those who could benefit from them and reduce the cost of preventing T2DM.

Predicting T2DM in healthy individuals has been attempted using a diabetes risk score that is derived from common clinical information, such as adiposity, blood pressure, and family history of T2DM. However, using the risk score is inevitably limited in predicting T2DM because T2DM has a strong genetic basis; concordance of T2DM is about 70% for monozygotic twins, compared to about 20--30% for dizygotic twins.^[@r02]^

Limitations in predicting T2DM have driven researchers to employ genetic risk assessments. Moreover, unlike clinical markers, genetic markers do not change with time, so they possess the advantage of identifying high-risk individuals long before disease onset, which could enable early interventions for preventing T2DM. Conventionally, family-based linkage studies have played an important role in identifying genes having a large effect in monogenic disorders, such as maturity-onset diabetes of the young.^[@r03]^ However, linkage studies have low power for polygenic diseases that are influenced by multiple genes, as is the case with the majority of those with T2DM. Therefore, using monogenic mutations would have very limited value for predicting risk of disease in the general population because of their low frequency.

Genome-wide association studies (GWAS) capture the great majority of common genetic differences among individuals and relate them to health and diseases.^[@r04]^ The GWAS potentially represent a powerful new tool for identifying genes that influence common diseases. Recently, GWAS identified an increasing number of loci associated with susceptibility to T2DM. However, each risk allele (RA) of single nucleotide polymorphisms (SNPs) at these loci has a modest effect size.^[@r05]^ Therefore, a combination of several SNPs is required to substantially influence T2DM risk. A genetic risk score potentially has the ability to predict disease risk as a function of the combined effects of SNPs. The most typical approach to produce the genetic risk score is to count the total number of RAs at each T2DM-associated SNP identified by GWAS. Because the number of RAs carried is consequently a quantifiable variable, it can be potentially used for clinical risk assessment, similar to measurement of body mass index (BMI). Recently, an increasing number of epidemiological studies have investigated the effect of cumulative RAs on T2DM risk. However, the quantitative association between cumulative RAs and T2DM risk has not been established, while the association of BMI with T2DM risk was quantified using meta-analysis.^[@r06]^ The aim of this meta-analysis is to comprehensively estimate the strength of the association between cumulative RAs and T2DM risk, including exploration of differences in the magnitude of T2DM risk according to several study characteristics.

MATERIALS AND METHODS
=====================

Literature searches
-------------------

Electronic literature search using EMBASE and MEDLINE (up to 2015) was conducted for studies that quantified the genetic risk of T2DM. This search was limited to articles published after the International HapMap Project had identified a majority of the common SNPs examined by GWAS in 2003.^[@r07]^ Manual searches were added using the reference list of each included study.

Inclusion criteria
------------------

Study keywords were thesaurus terms related to genetic profiles and T2DM (Table [1](#tbl01){ref-type="table"}). Inclusion criteria were: 1) cross-sectional design (for assessing the possibility of having undiagnosed T2DM) or longitudinal design (for assessing the risk of developing T2DM); 2) total number of RAs carried calculated by summing the number of RAs in each SNP according to an additive model (ie, 0, 1, and 2 were assigned for homozygosity for a non-RA, heterozygosity for an RA, and homozygosity for an RA, respectively) were analyzed as an exposure; 3) two or more SNPs were combined for assessing genetic risk; and 4) the odds ratio (OR) for each increment in the number of RAs carried (1-ΔRA) and its corresponding standard error (SE) (SE is usually provided for the natural logarithm of OR \[log OR\] rather than for the OR) were presented or could be estimated. Exceptionally, studies that used the dominant model (ie, counting 1 for homozygosity or heterozygosity for having an RA and 0 for having no RA) were also considered.

###### Study keywords for this meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Using EMBASE
  Terms related to thesaurus
  \#1   \[related to genetic backgrounds\]
  "genetic variability" OR "genetic polymorphism" OR "single nucleotide polymorphism \[Exp\]" OR "genetic association" OR "genotyping" OR "genetic susceptibility" OR "genetic resistance" OR "genetic predisposition"
  \#2   \[related to type 2 diabetes mellitus\]
  "non insulin dependent diabetes mellitus \-- epidemiology" OR "diabetes mellitus \-- epidemiology"
  \#3   \#1 AND \#2
  Using MEDLINE
  \#4   \[related to genetic backgrounds\]
  "Genome-Wide Association Study" OR "Genetic Association Studies" OR "Polymorphism, Single Nucleotide" OR "Genetic Variation \[Exp\]" OR "Polymorphism, Genetic \[Exp\]" OR "Genotype" OR "Genetic Predisposition to Disease"
  \#5   \[related to type 2 diabetes mellitus\]
  "Diabetes Mellitus, Type 2 \-- epidemiology" OR "Diabetes Mellitus, Type 2 \-- genetics" OR "Diabetes Mellitus \-- genetics" OR "Diabetes Mellitus \-- epidemiology"
  \#6   \#4 AND \#5
  Combination of EMBASE and MEDLINE
  \#7   \#3 OR \#6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\[Exp\] indicates automatic inclusion of all the narrower terms under the specified descriptor in the thesaurus hierarchy.

Using the connector "\--" limits a descriptor term to a Subheading appearing after the connector.

Haplotypes into which alignments of multiple SNPs were classified were regarded as one unit because these SNPs could not be separated into individual SNPs. Therefore, studies that examined the association between several haplotypes and T2DM risk were excluded, even if two or more SNPs were used. Due to the necessity of maintaining homogeneity across studies as closely as possible, the OR needed to be adjusted for at least two of the following three covariates: age, gender, and BMI. For the same reason, studies were excluded if they examined T2DM risk in relation to a weighted risk score that was produced by summing the number of RAs multiplied by the SNP-specific effect size. In longitudinal studies, if the risk measure was expressed as a relative risk (RR) rather than OR, we included such studies on the condition that the incidence rate in the study population was reported. In that case, the RR was converted into an OR using the following formula: ${OR} = \frac{{RR} \times (1 - \text{P}_{\text{o}})}{1 - \text{P}_{\text{o}} \times {RR}}$, in which the incidence rate was imputed to P~o~.^[@r08]^ Also, as the SE corresponding to the natural logarithm of RR (log RR) was converted into the SE corresponding to log OR, the Miettinen test-based approach was applied: $\text{SE}(\text{log}{OR}) = \text{SE}(\text{log}{RR}) \times \sqrt{\frac{\text{log}{OR}}{\text{log}{RR}}}$.^[@r09]^

Data extraction
---------------

For each included study, two authors (S.K. and H.So.) extracted the following information relevant to study characteristics: country, ethnic group (if information was presented), design (cross-sectional or longitudinal), observational periods (in case of a longitudinal study), number of participants and cases, mean age, proportion of men and women, mean BMI, study-specific covariates, criteria of T2DM cases and non-cases, and used SNPs. Inconsistencies were resolved via discussion. Study quality was assessed by 10 basic questions that should be answered in the affirmative to indicate a reliable report (Table [2](#tbl02){ref-type="table"}).^[@r04]^ One point was awarded to a study for each "Yes" answer, with a maximum score of 10.

###### Assessment of study quality using 10 basic questions about genome-wide association studies

  First author                 Year   Quality Score   Q.1   Q.2   Q.3   Q.4   Q.5   Q.6   Q.7   Q.8   Q.9   Q.10
  ---------------------------- ------ --------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ------
  Oian^[@r18]^                 2015   8               Yes   Yes   Yes   Yes   Yes   Yes   No    Yes   Yes   No
  Talmud^[@r17]^               2015   6               Yes   Yes   No    Yes   Yes   Yes   Yes   No    No    No
  Chen^[@r21]^                 2014   5               No    No    Yes   Yes   Yes   Yes   Yes   No    No    No
  Langenberg^[@r20]^           2014   5               No    Yes   No    Yes   Yes   Yes   Yes   No    No    No
  Villegas^[@r19]^             2014   3               No    No    No    No    Yes   Yes   Yes   No    No    No
  Anand^[@r26]^                2013   3               No    Yes   No    Yes   No    Yes   No    No    No    No
  Kalnina^[@r27]^              2013   5               Yes   No    No    Yes   Yes   No    Yes   No    No    Yes
  Imamura^[@r25]^              2013   5               Yes   No    Yes   Yes   Yes   Yes   No    No    No    No
  Peters^[@r28]^               2013   4               No    No    No    No    Yes   Yes   Yes   No    No    Yes
  Ramya^[@r24]^                2013   4               Yes   No    No    No    Yes   Yes   Yes   No    No    Yes
  Robiou-du-Pont^[@r23]^       2013   5               Yes   No    Yes   Yes   No    Yes   Yes   No    No    No
  Tam^[@r22]^                  2013   4               Yes   No    Yes   Yes   No    Yes   No    No    No    No
  Cauchi^[@r29]^               2012   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Cooke^[@r30]^                2012   5               Yes   No    Yes   Yes   Yes   Yes   No    No    No    No
  Gamboa-Meiendez^[@r31]^      2012   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Iwata^[@r32]^                2012   8               Yes   No    Yes   Yes   Yes   Yes   Yes   Yes   Yes   No
  Long^[@r33]^                 2012   5               Yes   No    Yes   Yes   Yes   Yes   No    No    No    No
  Vassy^[@r34]^                2012   3               Yes   Yes   No    No    No    Yes   No    No    No    No
  Vassy^[@r35]^                2012   3               Yes   Yes   No    No    Yes   No    No    No    No    No
  Villegas^[@r36]^             2012   5               Yes   No    Yes   Yes   Yes   Yes   No    No    No    No
  Yamakawa-Kobayashi^[@r37]^   2012   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Li^[@r38]^                   2011   3               No    Yes   No    Yes   No    Yes   No    No    No    No
  Martinez-Gomez^[@r39]^       2011   6               Yes   No    No    Yes   Yes   No    Yes   Yes   Yes   No
  Rees^[@r40]^                 2011   4               Yes   No    Yes   Yes   No    Yes   No    No    No    No
  Tabara^[@r41]^               2011   3               Yes   Yes   No    No    No    Yes   No    No    No    No
  Uusitupa^[@r42]^             2011   4               Yes   Yes   No    Yes   No    Yes   No    No    No    No
  Fontaine-Bisson^[@r43]^      2010   4               Yes   No    No    Yes   No    Yes   No    No    No    Yes
  Qi^[@r44]^                   2010   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Rotger^[@r45]^               2010   1               No    No    No    No    No    Yes   No    No    No    No
  Wang^[@r46]^                 2010   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Waters^[@r47]^               2010   2               No    No    Yes   No    No    Yes   No    No    No    No
  Xu^[@r48]^                   2010   7               Yes   Yes   Yes   Yes   Yes   Yes   Yes   No    No    No
  Cornelis^[@r49]^             2009   5               No    Yes   Yes   Yes   Yes   Yes   No    No    No    No
  Hu^[@r50]^                   2009   6               Yes   No    Yes   Yes   Yes   Yes   Yes   No    No    No
  Lin^[@r51]^                  2009   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Miyake^[@r52]^               2009   6               No    No    Yes   No    Yes   Yes   Yes   Yes   Yes   No
  Nordman^[@r53]^              2009   3               Yes   No    No    Yes   No    Yes   No    No    No    No
  Rong^[@r54]^                 2009   2               Yes   No    No    No    No    Yes   No    No    No    No
  Schulze^[@r55]^              2009   2               No    No    No    Yes   No    Yes   No    No    No    No
  Cauchi^[@r56]^               2008   7               Yes   No    Yes   Yes   Yes   Yes   Yes   Yes   No    No
  Lyssenko^[@r57]^             2008   7               Yes   No    Yes   Yes   Yes   Yes   No    Yes   Yes   No
  Meigs^[@r58]^                2008   4               Yes   No    No    Yes   Yes   Yes   No    No    No    No
  Vaxillaire^[@r59]^           2008   5               Yes   No    No    Yes   Yes   Yes   Yes   No    No    No
  Scott^[@r60]^                2006   4               Yes   No    No    Yes   Yes   Yes   No    No    No    No
  Hansen^[@r61]^               2005   5               Yes   No    No    Yes   Yes   Yes   No    No    No    Yes
  Zacharova^[@r62]^            2005   4               Yes   Yes   No    No    No    Yes   No    No    No    Yes

Each question used for assessment of study quality is given below.^[@r04]^ If the answer is "Yes" to a question, a study could be awarded 1 point. Full score is 10.

Q.1. Are the cases defined clearly and reliably so that they can be compared with patients typically seen in clinical practice?

Q.2. Are case and control participants demonstrated to be comparable to each other for important characteristics that might also be related to genetic variation and to the disease? In longitudinal studies, the answer was considered to be "Yes" if the diabetes risk was adjusted for age, gender, and obesity index.

Q.3. Was the study of sufficient size to detect modest odds ratios or relative risks (1.3--1.5)?

(At least 1,500 cases are needed to obtain 90% statistical power for detecting a 30% allelle with a 1.5 odds ratio at *P* \< 10^−8^ of a significant level.^\*^)

Q.4. Was the genotyping platform of sufficient density to capture a large proportion of the variation in the population studied?

Q.5. Were appropriate quality control measures applied to genotyping assays, including visual inspection of cluster plots and replication on an independent genotyping platform?

(The concordance rate needed to be presented by using a duplicate sample if the study met this criterion.)

Q.6. Did the study reliably detect associations with previously reported and replicated variants (known positives)?

Q.7. Were stringent corrections applied for the many thousands of statistical tests performed in defining the *P* value for significant associations?

Q.8. Were the results replicated in independent population samples?

Q.9. Were the replication samples comparable in geographic origin and phenotype definition, and if not, did the differences extend the applicability of the findings?

Q.10. Was evidence provided for a functional role for the gene polymorphism identified?

^\*^Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881--8.

If a study presented several ORs for T2DM with different levels of adjustment, the most completely adjusted OR was chosen. If a study presented several ORs with different combinations of SNPs used for T2DM screening, the OR that had the greatest effect size was chosen. In addition, if a study performed both overall and subgroup analyses, we chose the data based on subgroup analyses if characteristics, such as mean age, proportion of men, and mean BMI, in each subgroup were described; otherwise, data based on an overall analysis were chosen.

Data synthesis
--------------

Most of the included studies did not directly present data on the OR for the increment in the number of RAs carried. To estimate the OR, the log ORs in several genetic risk groups in the individual study were regressed to their corresponding mean number of RAs carried.^[@r10]^ If data on the mean number of RAs carried could not be directly extracted, the midpoint value of the upper and lower boundaries of the number of RAs carried was used for intermediate categories. In other categories (ie, highest or lowest category), we assumed that the frequency distribution of the number of RAs carried was normal and regressed the number of RAs carried to its corresponding Z-value for the rank percentile in the upper and lower boundary in each intermediate category and extrapolated the regression line into the highest and lowest categories. This regression is called generalized least squares for trend estimation (GLST), for which a program was developed by Orsini et al.^[@r11]^ This program can calculate a weighted linear regression of log OR across categories of the number of RAs carried with consideration of the covariance among the log ORs as long as data on the total number of participants and cases are provided.

Cross-sectional studies and longitudinal studies were analyzed separately. In each study, the OR of T2DM for 1-ΔRA was transformed into log OR because its corresponding SE is provided for log OR rather than for the OR. The log OR was pooled with a random-effects model^[@r12]^ followed by exponentiation of the pooled log OR to obtain the OR of interest. Study heterogeneity was assessed by Q-statistics or I-squared overall and within each strata after stratification.^[@r13]^

Publication bias was assessed by two formal statistical tests: Begg's rank correlation test^[@r14]^ and Egger's regression asymmetry test.^[@r15]^ For statistically suspected publication bias, the trim and fill method was adopted to adjust the pooled T2DM risk, assuming that the asymmetry of the funnel plot is entirely due to publication bias. This method includes detection of unpublished studies that distorted the funnel plot, filling the results of these hypothetical studies to recover the symmetry of the funnel plot, and recalculation of the pooled effect size as if these studies had actually existed.^[@r16]^

Sensitivity analysis
--------------------

The pooled OR was estimated for subgroups after stratification on the basis of the following pre-specified study characteristics: number of SNPs (\<10 or ≥10), mean age (\<55 years or ≥55 years in cross-sectional studies; \<50 years or ≥50 years in longitudinal studies), proportion of men (\<50% or ≥50%), country where the study was conducted (Western or non-Western), ethnic group (Asian or non-Asian), mean BMI (\<27 kg/m^2^ or ≥27 kg/m^2^ in cross-sectional studies; \<25 kg/m^2^ or ≥25 kg/m^2^ in longitudinal studies), whether the OR was or was not adjusted for BMI, whether the oral glucose tolerance test (OGTT) was thoroughly performed for detecting any cases of T2DM, and whether subjects with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) were excluded from non-T2DM cases. The cut-off values for mean age and BMI used in the stratified analyses corresponded to these median values in cross-sectional and longitudinal studies (median age: 55.7 years for cross-sectional studies and 50.6 years for longitudinal studies; median BMI: 26.7 kg/m^2^ for cross-sectional studies and 25.9 kg/m^2^ for longitudinal studies). Univariate log-linear meta-regression analysis was used to test the differences in the magnitude of the OR between strata.

Multivariate log-linear meta-regression analyses were added using several study characteristics simultaneously as explanatory variables. In these regression analyses, log OR of T2DM for 1-ΔRA was used as an objective variable. The T2DM-susceptible genes that were used in each study were inconsistent. Therefore, we added a meta-regression analysis of whether or not each of these genes was examined. This analysis was limited to the top 10 of the commonly used genes in this meta-analysis in order to maintain statistical power. All analyses were based on statistical software STATA version 14 (STATA Corp., College Station, TX, USA). The meta-regression analyses were performed by installing the "metareg" command into STATA. We also installed the "glst" command to estimate the OR for carrying 1-ΔRA using GLST.

RESULTS
=======

Eligible studies
----------------

Figure [1](#fig01){ref-type="fig"} is a flow chart showing the procedure for identifying studies that met the initial inclusion criteria. Of 7,381 studies retrieved through the electronic literature search, 96 investigated the genetic risk for T2DM combining two or more SNPs. After 10 studies in which the study population overlapped with other studies were eliminated, there remained 86 studies for further review. Forty studies did not allow estimation of the adjusted OR for T2DM for one increment in risk alleles carried. Finally, 46 original studies^[@r17]--[@r62]^ in which the OR for T2DM for 1-ΔRA was presented or could be estimated, including 75,651 cases among 249,365 participants, were eligible. Twenty-eight studies^[@r17],[@r19],[@r20],[@r23],[@r26],[@r27],[@r29],[@r30],[@r33]--[@r35],[@r38],[@r40],[@r42],[@r43],[@r45]--[@r47],[@r49],[@r51],[@r53],[@r55]--[@r60],[@r62]^ analyzed T2DM risk in Western countries. Table [3](#tbl03){ref-type="table"} shows characteristics of the 46 eligible studies. Most studies were not considered to have targeted exclusively a single ethnicity, and only 5 studies^[@r19],[@r26],[@r39],[@r47],[@r57]^ performed analyses by ethnicity. Only 2 studies^[@r49],[@r62]^ analyzed men and women separately, and all but 3 studies^[@r37],[@r46],[@r53]^ included both genders. One study^[@r48]^ analyzed T2DM risk from both cross-sectional and longitudinal perspectives.

![Flowchart of search for eligible studies](je-28-003-g001){#fig01}

###### Characteristics of each eligible study analyzed in this meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                 Year    Country     Design   Follow-up duration^a^\   Subgroup                      Number of participants   Number of cases   Mean age   \% men   BMI
                                                            (years)                                                                                                               
  ---------------------------- ------- ----------- -------- ------------------------ ----------------------------- ------------------------ ----------------- ---------- -------- ------------
  Oian^[@r18]^                 2015    China       C                                                               6,063                    2,853             57.3       37.5%    23.5

  Talmud^[@r17]^               2015    UK          L        10                                                     13,294                   804               N/A        59.5%    N/A

  Chen^[@r21]^                 2014    Singapore   C                                                               4,677                    2,338             55.2       47.1%    23.6

  Langenberg^[@r20]^           2014    UK          L        8.9                                                    18,890                   8,245             52.3       38.0%    26.7

  Villegas^[@r19]^             2014    USA         C                                 Non-Hispanic Whites           6,377                    545               52.8       45.0%    27.4

  Non-Hispanic Blacks          3,054   337         43.7     44.0%                    28.9                                                                                         

  Mexican Americans            3,621   455         43.6     49.0%                    28.2                                                                                         

  Anand^[@r26]^                2013    Canada      L        3.3                      European                      5,449                    586               55.0       39.2%    30.4

  South African                2,268   194         44.9     51.6%                    26.4                                                                                         

  Latinos                      2,815   218         52.6     33.2%                    30.8                                                                                         

  Imamura^[@r25]^              2013    Japan       C                                                               4,399                    2,613             58.1       45.2%    23.8

  Kalnina^[@r27]^              2013    Latvia      C                                                               2,047                    981               56.7       32.1%    29.7

  Peters^[@r28]^               2013    Australia   C                                                               3,322                    967               55.7       47.4%    26.9

  Ramya^[@r24]^                2013    India       C                                                               1,957                    940               45.8       44.3%    24.3

  Robiou-du-Pont^[@r23]^       2013    France      C                                                               5,162                    2,077             54.5       43.5%    26.7

  Tam^[@r22]^                  2013    China       C                                                               8,451                    5,882             52.2       46.1%    24.1

  Cauchi^[@r29]^               2012    France      C                                                               2,248                    1,193             56.1       32.5%    28.1

  Cooke^[@r30]^                2012    USA         C                                                               4,045                    2,652             55.7       41.9%    30.9

  Gamboa-Meiendez^[@r31]^      2012    Mexico      C                                                               2,017                    1,027             53.5       37.6%    28.6

  Iwata^[@r32]^                2012    Japan       C                                 Other than Tokyo University   1,487                    724               68.8       54.5%    23.6

  Tokyo University             2,041   1,182       67.1     53.2%                    24.0                                                                                         

  Long^[@r33]^                 2012    USA         C                                                               4,288                    1,554             56.8       30.7%    31.5

  Vassy^[@r34]^                2012    USA         L        23.9                                                   2,439                    215               25.1       44.0%    24.3

  Vassy^[@r35]^                2012    USA         L        26.9                                                   1,030                    90                14.4       44.7%    20.7

  Villegas^[@r36]^             2012    China       C                                                               6,001                    2,679             55.6       23.8%    26.4

  Yamakawa-Kobayashi^[@r37]^   2012    Japan       C                                                               750                      333               54.0       100%     23.9

  Li^[@r38]^                   2011    UK          L        12.9                                                   21,157                   729               58.9       49.8%    26.5

  Martinez-Gomez^[@r39]^       2011    Mexico      C                                 Guerrero                      400                      200               50.7       36.0%    28.2

  Mexico                       1,065   546         48.6     50.5%                    28.4                                                                                         

  Rees^[@r40]^                 2011    UK          C                                                               3,262                    1,659             55.8       49.4%    26.3

  Tabara^[@r41]^               2011    Japan       L        9.4                                                    1,824                    95                62.0       54.4%    23.5

  Uusitupa^[@r42]^             2011    Finland     L        6.2                                                    522                      185               55.4       32.8%    31.2

  Fontaine-Bisson^[@r43]^      2010    Sweden      C                                                               2,751                    1,327             53.3       54.2%    27.6

  Qi^[@r44]^                   2010    China       C                                                               2,332                    424               58.8       42.8%    24.2

  Rotger^[@r45]^               2010    Swiss       C                                                               644                      94                39.9       79.5%    23.2

  Wang^[@r46]^                 2010    Finland     C                                                               7,232                    518               57.7       100%     27.0

  Waters^[@r47]^               2010    USA         C                                 African-Americans             2,546                    1,077             60.2       40.9%    28.6

  Native Hawaiians             1,559   576         55.6     48.2%                    28.7                                                                                         

  European-Americans           1,539   533         57.6     51.5%                    26.6                                                                                         

  Latinos                      4,404   2,220       59.3     48.0%                    27.7                                                                                         

  Japanese                     3,497   1,736       59.2     56.2%                    25.2                                                                                         

  Xu^[@r48]^                   2010    China       C                                                               5,512                    1,825             61.1       40.9%    25.2

  L                            3.5                 734      67                       60.0                          39.0%                    24.8                                  

  Cornelis^[@r49]^             2009    USA         L        10                                                     6,310                    2,809             48.5       40.2%    25.9

  Hu^[@r50]^                   2009    China       C                                                               3,634                    1,849             59.3       46.9%    23.8

  Lin^[@r51]^                  2009    USA         C                                                               5,360                    356               53.3       47.4%    25.8

  Miyake^[@r52]^               2009    Japan       C                                                               4,678                    2,316             64.4       52.1%    23.5

  Nordman^[@r53]^              2009    Sweden      C                                                               771                      243               52.3       100%     29.5

  Rong^[@r54]^                 2009    Iadia       C                                                               2,745                    1,161             33.7       N/A      36.9

  Schulze^[@r55]^              2009    Germany     L        7                                                      2,541                    579               50.6       51.1%    26.9

  Cauchi^[@r56]^               2008    France      C                                                               8,827                    4,232             58.6       41.9%    26.7

  Lyssenko^[@r57]^             2008    Sweden      L        23.5                     Malmo                         16,061                   2,063             45.5       51.7%    24.3

  Botnia                       2,770   138         44.9     64.9%                    25.6                                                                                         

  Meigs^[@r58]^                2008    USA         L        28                                                     2,434                    255               35.0       45.5%    24.9

  Vaxillaire^[@r59]^           2008    France      L        9                                                      3,442                    292               47.7       46.8%    24.3

  Scott^[@r60]^                2006    USA         C                                                               2,104                    1,151             64.2       44.3%    28.4

  Hansen^[@r61]^               2005    Denmark     C                                                               5,897                    1,164             48.4       55.8%    26.3

  Zacharova^[@r62]^            2005    Finland     L        3.3                                                    223                      102               54.7       49.5%    30.9^\*\*^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; C, cross-sectional; L, longitudinal.

^a^In study using longitudinal design.

Table [4](#tbl04){ref-type="table"} summarizes the criteria for T2DM cases and non-cases in each study. OGTT was used for any participant in whom T2DM was undiagnosed using other methods in 20 studies.^[@r22],[@r24],[@r26],[@r30],[@r37],[@r40],[@r43],[@r45],[@r46],[@r48]--[@r50],[@r53],[@r54],[@r57],[@r58],[@r60]--[@r63]^ Among cross-sectional studies, 7 studies^[@r24],[@r48],[@r50],[@r53],[@r54],[@r60],[@r61]^ and 13 studies^[@r18],[@r29],[@r31],[@r33],[@r36],[@r37],[@r44],[@r48],[@r50],[@r53],[@r56],[@r60],[@r64]^ excluded participants with IGT and IFG, respectively, from non-T2DM cases. Table [5](#tbl05){ref-type="table"} shows details of covariates that each study arbitrarily considered. Study-specific covariates were heterogeneous among studies. However, T2DM risk was adjusted for BMI in most studies (37 studies).^[@r17]--[@r20],[@r22]--[@r28],[@r31]--[@r38],[@r40]--[@r42],[@r44]--[@r56],[@r59],[@r62]^

###### Criteria for cases and non-cases in each included study

  First author                 Design                                   Criteria                                                 
  ---------------------------- ---------------------------------------- -------------------------------------------------------- -----------------------------------------------------------------------------------------
  Oian^[@r18]^                 C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 5.6 mmol/l
  Talmud^[@r17]^               L                                        self-report or FPG ≥ 7.0 mmol/l                          FPG \< 7.0 mmol/l
  Chen^[@r21]^                 C                                        interview or A1C \> 6.0%                                 A1C ≤ 6.0%
  Langenberg^[@r20]^           L                                        self-report, registry, medical record                    unclear
  Villegas^[@r19]^             C                                        questionnaire                                            questionnaire
  Anand^[@r26]^                L                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   IFG or IGT
  Kalnina^[@r27]^              C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Imamura^[@r25]^              C                                        registry                                                 registry
  Peters^[@r28]^               C                                        unclear                                                  unclear
  Ramya^[@r24]^                C                                        2hPG ≥ 11.1 mmol/l                                       2hPG \< 7.8 mmol/l
  Robiou-du-Pont^[@r23]^       C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mmol/l
  Tam^[@r22]^                  C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   unclear
  Cauchi^[@r29]^               C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 5.6 mmol/l
  Cooke^[@r30]^                C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Gamboa-Meiendez^[@r31]^      C                                        casual PG ≥ 11.1 mmol/l or FPG ≥ 7.0 mmol/l              FPG \< 5.6 mmol/l, no FH of DM
  Iwata^[@r32]^                C                                        unclear                                                  A1C \< 6.0%
  Long^[@r33]^                 C                                        casual PG ≥ 11.1 mmol/l or A1C ≥ 6.5%                    FPG \< 6.1 mmol/l, A1C \< 6.0%
  Vassy^[@r34]^                L                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mmol/l
  Vassy^[@r35]^                L                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mmol/l
  Villegas^[@r36]^             C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 5.6 mmol/l, A1C \< 6.1%
  Yamakawa-Kobayashi^[@r37]^   C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 5.6 mmol/l, A1C \< 5.8%
  Li^[@r38]^                   L                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mol/l
  Martinez-Gomez^[@r39]^       C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mol/l
  Rees^[@r40]^                 C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 5.6 mmol/l or (FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l) or casual PG \< 6.7 mmol/l
  Tabara^[@r41]^               L                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Uusitupa^[@r42]^             L                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.8 mmol/l, 2hPG \< 11.1 mmol/l
  Fontaine-Bisson^[@r43]^      C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Qi^[@r44]^                   C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 5.6 mmol/l
  Rotger^[@r45]^               C                                        casual PG ≥ 11.1 mmol/l or FPG ≥ 7.0 mmol/l              casual PG \< 11.1 mmol/l, FPG \< 7.0 mmol/l
  Wang^[@r46]^                 C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Waters^[@r47]^               C                                        unclear                                                  unclear
  Xu^[@r48]^                   C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l
  L                            FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l                   
  Cornelis^[@r49]^             L                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.8 mmol/l, 2hPG \< 11.1 mmol/l
  Hu^[@r50]^                   C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l
  Lin^[@r51]^                  C                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mmol/l
  Miyake^[@r52]^               C                                        physician diagnosis for Japanese, registry for Chinese   A1C \< 5.6% for Japanese, FPG \< 6.1 mmol/l for Chinese
  Nordman^[@r53]^              C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l
  Rong^[@r54]^                 C                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.8 mmol/l, 2hPG \< 11.1 mmol/l
  Schulze^[@r55]^              L                                        questionnaire                                            questionnaire
  Cauchi^[@r56]^               C                                        casual PG ≥ 11.1 mmol/l or FPG ≥ 7.8 mmol/l              FPG \< 6.1 mmol/l, no FH of DM
  Lyssenko^[@r57]^             L                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Meigs^[@r58]^                L                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 7.0 mmol/l, 2hPG \< 11.1 mmol/l
  Vaxillaire^[@r59]^           L                                        FPG ≥ 7.0 mmol/l                                         FPG \< 7.0 mmol/l
  Scott^[@r60]^                C                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l
  Hansen^[@r61]^               C                                        FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l                   FPG \< 6.1 mmol/l, 2hPG \< 7.8 mmol/l
  Zacharova^[@r62]^            L                                        FPG ≥ 7.8 mmol/l or 2hPG ≥ 11.1 mmol/l                   7.8 mmol/l = \< 2hPG \< 11.1 mmol/l, FPG \< 7.8 mmol/l

2hPG, 2-hour post glucose concentration; A1C, hemoglobin A~1C~; ADA, American Diabetes Association criteria for diabetes; FH of DM, family history of diabetes mellitus; FPG, fasting plasma glucose; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.

###### Details of covariates considered in each included study

  ----------------------------------------------------------------------------------------------------------
  First author                 Year   Covariates
  ---------------------------- ------ ----------------------------------------------------------------------
  Oian^[@r18]^                 2015   age, gender, BMI

  Talmud^[@r17]^               2015   age, gender, BMI, BP, HDL, TG

  Chen^[@r21]^                 2014   age, gender, dialect, global ancestry

  Langenberg^[@r20]^           2014   age, gender, BMI

  Villegas^[@r19]^             2014   age, gender, BMI

  Anand^[@r26]^                2013   age, gender, BMI, WC, FHDM, smoking, PA, Apo-A, Apo-B, HT

  Imamura^[@r25]^              2013   age, gender, BMI

  Kalnina^[@r27]^              2013   age, gender, BMI

  Peters^[@r28]^               2013   age, gender, BMI, adiponectine

  Ramya^[@r24]^                2013   age, gender, BMI

  Robiou-du-Pont^[@r23]^       2013   age, gender, BMI

  Tam^[@r22]^                  2013   age, gender, BMI

  Cauchi^[@r29]^               2012   age, gender

  Cooke^[@r30]^                2012   age, gender

  Gamboa-Meiendez^[@r31]^      2012   age, gender, BMI

  Iwata^[@r32]^                2012   age, gender, BMI

  Long^[@r33]^                 2012   age, gender, BMI

  Vassy^[@r34]^                2012   age, gender, race, FH of DM, BMI, FPG, HDL, TG, PA, smoking, alcohol

  Vassy^[@r35]^                2012   age, gender, race, FH, BMI, MAP, FPG, HDL, TG

  Villegas^[@r36]^             2012   age, gender, BMI

  Yamakawa-Kobayashi^[@r37]^   2012   age, gender, BMI

  Li^[@r38]^                   2011   age, gender, BMI

  Martinez-Gomez^[@r39]^       2011   age, gender

  Rees^[@r40]^                 2011   age, gender, BMI

  Tabara^[@r41]^               2011   age, gender, BMI

  Uusitupa^[@r42]^             2011   age, gender, BMI, BMI change, FH, intervention, FPG, 2hPG,\
                                      FPG change, 2hPG change, insulin, insulin change, 2h-insulin,\
                                      2h-insulin change

  Fontaine-Bisson^[@r43]^      2010   age, gender

  Qi^[@r44]^                   2010   age, gender, BMI

  Rotger^[@r45]^               2010   age, gender, BMI, treatment for HIV, CD4+, HDL, TG

  Wang^[@r46]^                 2010   \#\# FINDRISC score, TG, HDL, ALT, adiponectine

  Waters^[@r47]^               2010   age, gender, BMI

  Xu^[@r48]^                   2010   age, gender, BMI, FH of DM, smoking, alcohol

  Cornelis^[@r49]^             2009   age, gender, BMI, FH of DM, smoking, alcohol, PA

  Hu^[@r50]^                   2009   age, gender, BMI

  Lin^[@r51]^                  2009   age, BMI, FH of DM, TG/HDL, PA

  Miyake^[@r52]^               2009   age, gender, BMI

  Nordman^[@r53]^              2009   age, (gender), BMI, SBP, DBP

  Rong^[@r54]^                 2009   age, gender, BMI

  Schulze^[@r55]^              2009   DRS score^a^, HDL, TG, ALT

  Cauchi^[@r56]^               2008   age, gender, BMI

  Lyssenko^[@r57]^             2008   age, gender

  Meigs^[@r58]^                2008   age, gender

  Vaxillaire^[@r59]^           2008   age, gender, BMI

  Scott^[@r60]^                2006   age, gender, birth province

  Hansen^[@r61]^               2005   age, gender

  Zacharova^[@r62]^            2005   age, (gender), BW, BW change, smoking, country
  ----------------------------------------------------------------------------------------------------------

ALT, alanine aminotransferase; BMI, body mass index; CD4, cluster of differentiation 4; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; FH of DM, family history of diabetes mellitus; FPG, fasting plasma glucose; HIV, human immunodeficiency virus; MAP, mean arterial blood pressure; SBP, systolic blood pressure; TG, triglycerides; PA, physical activity.

^a^Including age, BMI, waist circumferences, PA, vegetable intake, past history of hyperglycemia, and taking anti-hypertensive agents \#\#\# including age, waist circumferences, height, hypertension, PA, smoking, meat intake, intake of whole-grain bread, coffee, and alcohol.

Table [2](#tbl02){ref-type="table"} describes the assessment of study quality. No study received a full score of 10. Also, there were some "no" responses to each of the items. Mean (standard deviation) score was 4.3 (1.6). Table [6](#tbl06){ref-type="table"} summarizes the T2DM-associated loci used in each study. The number of SNPs ranged from 2 to 65 (median, 14.0 SNPs). Table [7](#tbl07){ref-type="table"} indicates the rank of the genes that were commonly used in association with prevalent or incident T2DM. The top 10 genes were *CDKAL1*, *TCF7L2*, *CDKN*, *HHEX*, *IGFBP2*, *SLC30A8*, *KCNJ11*, *PPARG*, *FTO*, and *KCNQ1*. Total number of SNPs that were covered by at least one of the included studies was 116.

###### Details of genes used in each included study that are associated with type 2 diabetes mellitus

  First author                 Year   Number of SNPs    
  ---------------------------- ------ ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Oian^[@r18]^                 2015   9                *CDKAL1, CDKN2A/2B, CENTD2, FTO, HHEX* (2 SNP*s*), *KCNQ1, SLC30A8, VEGFA*
  Talmud^[@r17]^               2015   65               *ADAMTS9, ADCY5, ANK1, ANKRD55, AP3S2, BCAR1, BCL11A, C2CD4A, CCND2, CDC123/CAMK1D, CDKAL1, CDKN2A/B, CENTD2, CILP2, DGKB, DUSP8, FTO, GCC1, GCK, GCKR, GIPR, GLIS3, GRB14, HHEX/IDE, HMG20A, HMGA2, HNF1A, HNF1B, HNF4A, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNK16, KCNQ1, KLF14, KLHDC5, MAEA, MC4R, MTNR1B, NOTCH2, PEPD, PPARG, PRC1, PROX1, PSMD6, PTPRD, RBMS1, SLC30A8, SPRY2, SRR, ST64GAL1, TCF7L2, THADA, TLE1, TLE4, TP53INP1, TSPAN8/LGR5, UBE2E2, VPS26A, WFS1, ZBED3, ZFAND3, ZFAND6, ZMIZ1*
  Chen^[@r21]^                 2014   19               *ADAMTS9-MAGI1, ANK1, BCL11A-EIF3FP3, C6orf57, CDC123-CAMK1D, CDKAL1, CDKN2A/2B* (2 SNP*s*), *FTO, HHEX-EPOC6, HNF4A, IGF2BP2* (2 SNP*s*), *IRS1-KIAA1486, KLF14-FLJ43663, PTPRD, THADA, TSPAN8-LGR5, VPS26A*
  Langenberg^[@r20]^           2014   49               *ADAMTS9, ADCY5, ANK1, ANKRD55, BCAR1, BCL11A, CCND2, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, CENTD2, CILP2, DUSP9, DGKB, FTO, GCK, GCKR, GIPR, GRB14, HHEX-IDE, HMG20A, HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, KCNJ11, KCNQ1, KLF14, KLHDC5, MC4R, MTNR1B, NOTCH2, PPARG, PRC1, PROX1, SLC30A8, SPRY2, TCF7L2, THADA, TLE1, TLE4, TP53INP1, TSPAN8-LGR5, UBE2E2, WFS1, ZBED3, ZFAND6, ZMIZ1*
  Imamura^[@r25]^              2014   10               *ANK1, C2CD4A/B, CDKAL1, CDKN2A/B, DUSP9, IGF2BP2, KCNQ1, MAEA, TCF7L2, UBE2E2*
  Villegas^[@r19]^             2014   15               *ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, IGF2BP2, JAZF1, KCNQ1, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8-LGR5*
  Anand^[@r26]^                2013   16               *CDKAL1, CDKN2A/2B, FTO, GATAD2A, GCKR, HHEX-IDE, HNF1B, IGF2BP2, IRS1, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8, TCF7L2, WFS1*
  Kalnina^[@r27]^              2013   2                *FTO, TMEM18*
  Peters^[@r28]^               2013   3                *ADIPOQ* (3 SNP*s*)
  Ramya^[@r24]^                2013   5                *ADIPOQ* (5 SNP*s*)
  Robiou-du-Pont^[@r23]^       2013   24               *AIF1, BDNF* (2 SNP*s*), *CTNNBL1, ETV5, FAIM2, FTO* (2 SNP*s*), *GNPDA2, KCTD15, MAF, MC4R, MTCH2, NEGR1, NPC1, PCSK1* (2 SNP*s*), *PRL, PTER, SDCCAG8, SEC16B, SH2B1, TMEM18, TNKS*
  Tam^[@r22]^                  2013   14               *ADAMTS9, CDKAL1, CDKN2A/2B, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, NOTCH2, SLC30A8, TCF7L2, TSPAN8-LGR5, WFS1*
  Cauchi^[@r29]^               2012   13               *ADAMTS9, BCL11A, CDKAL1, CDKN2A/2B, FTO, GCK, HNF1A, IGF2BP2, KCNQ1, MC4R, TCF7L2, TP53INP1, WFS1*
  Cooke^[@r30]^                2012   17               *ADAMTS9, CDKAL1, CDKN2A/2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8-LGR5, WFS1*
  Gamboa-Meiendez^[@r31]^      2012   21               *ADAMTS9, ARHGEF11, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, FTO, HHEX* (2 SNP*s*), *IGF2BP2, JAZF1, KCNJ11, KCNQ1, NXPH1, NOTCH2, PPARG, RALGPS2, RORA, SLC30A8, TCF7L2, TSPAN8-LGR5, UBQLNL*
  Iwata^[@r32]^                2012   14               *CDKAL1, CDKN2B, GCKR, HHEX, IGF2BP2, IRS1, KCNJ11, KCNQ1, PPARG, PRC1, PROX1, SLC30A8, TCF7L2, UBE2E2*
  Long^[@r33]^                 2012   29               *ADAMTS9, BCL11A, C2CD4A/B, CDKAL1* (2 SNP*s*), *CDKN2A/2B, CHCHD9, FTO, HHEX, HHEX-IDE, HMGA2, HNF1A, IGF2BP2* (2 SNP*s*), *JAZF1, KCNQ1* (3 SNP*s*), *KLF14, NOTCH2-ADAM30, RBMS1-ITGB6, SRR, TCF7L2, THADA, TSPAN8-LGR5, WFS1* (2 SNP*s*), *ZBED3, ZFAND6*
  Vassy^[@r34]^                2012   38               *ADAMTS9, ADCY5, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, CENTD2, DCD, DGKB-TMEM195, FTO, GCK, GCKR, HCCA2, HHEX, HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNQ1* (2 SNP*s*), *KLF14, MTNR1B, NOTCH2, PPARG, PRC1, PROX1, RBMS1-ITGB6, SLC30A8, TCF7L2, THADA, TLE4, TP53INP1, TSPAN8-LGR5, VEGFA, WFS1*
  Vassy^[@r35]^                2012   38               *ADAMTS9, ADCY5, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, CENTD2, DCD, DGKB-TMEM195, FTO, GCK, GCKR, HCCA2, HHEX, HMGA2, HNF1A, HNF1B, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNQ1* (*2* SNP*s*), *KLF14, MTNR1B, NOTCH2, PPARG, PRC1, PROX1, RBMS1-ITGB6, SLC30A8, TCF7L2, THADA, TLE4, TP53INP1, TSPAN8-LGR5, VEGFA, WFS1*
  Villegas^[@r36]^             2012   14               *CDC123-CAMK1D, CDKAL1* (*2* SNP*s*), *CDKN2A/2B, HHEX-IDE* (*2* SNP*s*), *HNF1B, IGF2BP2, KCNJ11, KCNK15, KCNQ1, SLC30A8, SPRY2, TP53INP1*
  Yamakawa-Kobayashi^[@r37]^   2012   17               *ADAMTS9, CDC123, CDC24A, CDKAL1, CDKN2A/2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2, TSPAN8, UBE2E2*
  Li^[@r38]^                   2011   12               *BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2Bi, TMEM18*
  ^\*^Martinez-Gomez^[@r39]^   2011   5                *CaPN10, IRS1, PPARG, TCF7L2* (2 SNP*s*)
  Rees^[@r40]^                 2011   28               *ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, CENTD2, CHCHD9, DUSP9, FTO, HHEX-IDE, HNF1A, IGF2BP2, IRS1, JAZF1, KCNJ11, KCNQ1* (2 SNP*s*), *KLF14, NOTCH2, PPARG, PRC1, SLC30A8, TCF7L2, THADA, TP53INP1, TSPAN8-LGR5, WFS1, ZBED3*
  Tabara^[@r41]^               2011   10               *CDKAL1, CDKN2A/2B, GCKR, HHEX, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2*
  Uusitupa^[@r42]^             2011   19               *ADAMTS9, CDC123, CDKAL1, CDKN2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, MTNR1B, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8, WFS1*
  Fontaine-Bisson^[@r43]^      2010   17               *CDC123-CAMK1D, CDKN2A/2B, DCD, EXT2, HHEX* (2 SNPs), *HNF1B, KCNJ11, LOC387761, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8-LGR5, VEGFA, WFS1*
  Qi^[@r44]^                   2010   17               *ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, GCKR, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8, TCF7L2, TSPAN-LGR5, WFS1*
  Rotger^[@r45]^               2010   4                *FTO, KCNJ11, TCF7L2, TSPAN-LGR5*
  Wang^[@r46]^                 2010   20               *ADAMTS9, CDC123, CDKAL1, CDKN2A/2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, KCNQ1, LOC387761, MTNR1B, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8, WFS1*
  Waters^[@r47]^               2010   19               *ADAMTS9, CDC123, CDKAL1, CDKN2A/2B, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11,*(2 SNP*s*), *NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8, WFS1*
  Xu^[@r48]^                   2010   4                *CDKAL1, CDKN2A/2B, KCNQ1, SLC30A8*
  Cornelis^[@r49]^             2009   10               *CDKAL 1, CDKN2A/2B* (2 SNP*s*), *HHEX, IGF2BP2, KCNJ11, PPARG, SLC30A8, TCF7L2, WFS1*
  Hu^[@r50]^                   2009   11               *CDKAL1, CDKN2A/2B, FTO, HNF1B, IDE-KIF11-HHEX, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, WFS1*
  Lin^[@r51]^                  2009   15               *ADAMTS9, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, FTO, HHEX-IDE, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG, TCF7L2, THADA, TSPAN-LGR5, WFS1*
  Miyake^[@r52]^               2009   11               *CDKAL1, CDKN2B, GCKR, HHEX, HNF1B, IGF2BP2, KCNJ11, KCNQ1, PPARG, SLC30A8, TCF7L2*
  Nordman^[@r53]^              2009   3                *HHEX, IDE, TCF7L2*
  Rong^[@r54]^                 2009   7                *CDKAL1, CDKN2B, FTO, HHEX, IGF2BP2, SLC30A8, TCF7L2*
  Schulze^[@r55]^              2009   20               *ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, DCD, FTO, HHEX, HNF1B, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8-LGR5, VEGFA, WFS1*
  Cauchi^[@r56]^               2008   15               *CAMTA1, CDKAL1, CDKN2A/2B, CXCR4, EXT2, HHEX, IGF2BP2, KCTD12, LDLR, LOC387761,*
  Lyssenko^[@r57]^             2008   11               *CDKAL1, FTO, HHEX, IGF2BP2, JAZF1, KCNJ11, NOTCH2, PPARG, SLC30A8, TCF7L2WFS1*
  Meigs^[@r58]^                2008   18               *ADAMTS9, BCL11A, CDC123-CAMK1D, CDKAL1, CDKN2A/2B, DCD, HHEX, IGF2BP2, INS, JAZF1, KCNJ11, NOTCH2, PPARG, SLC30A8, TCF7L2, THADA, TSPAN8-LGR5, VEGFA*
  Vaxillaire^[@r59]^           2008   3                *GCK, IL6, TCF7L2*
  Scott^[@r60]^                2006   3                *KCNJ11, PPARG, TCF7L2*
  Hansen^[@r61]^               2005   2                *KCNJ11, PPARG*
  ^\*^Zacharova^[@r62]^        2005   2                *ADIPOQ* (2 SNPs)

SNP, single nucleotide polymorphism.

^\*^The 2 studies used a dominant model.

The other studies used an additive model.

###### Rank of the number of genes that were used to examine the association with the prevalence or incidence of type 2 diabetes mellitus

  Number of studies   Genes
  ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  34                  *CDKAL1, TCF7L2*
  33                  *CDKN, HHEX*
  31                  *IGFBP2*
  29                  *SLC30A8*
  28                  *KCNJ11*
  27                  *PPARγ*
  25                  *FTO, KCNQ1*
  21                  *TCF1B, TSPAN8*
  20                  *ADAMST9, WFS1*
  19                  *JAZF1*
  18                  *NOTCH2*
  17                  *CDC123*
  16                  *THADA*
  10                  *BCL11A*
  9                   *GCKR, IRS1*
  8                   *HNF1A*
  7                   *KLF14, MTNR1B, TP53INP1*
  6                   *CENTD2, GCK, PRC1, VEGFA*
  5                   *DCD, HMGA2, MC4R, PROX1, UBE2E2*
  4                   *ADCY5, ANK1, DGKB, TLE4, RBMS1-ITGB6, ZBED3*
  3                   *ADIPOQ, C2CD4A/B, DUSP9, LOC387761, SPRY2, ZFAND6*
  2                   *ANKRD55, BCAR1, BDNF, CCND2, CHCHD9, CILP2, ETV5, EXT2, FAIM2, GIPR, GNPDA2, GRB14, HCCA2, HMG20A, KCTD15, KLHDC5, MAEA, MTCH2, NEGR1, PTPRD, SEC16B, SH2B1, SRR, TLE1, VPS26A, ZMIZ1*
  1                   *AIF1, AMTA1, AP3S2, ARHGEF11, C6orf57, CaPN10, CDC24A, CTNNBL1, CXCR4, DUSP8, EXT2, GATAD2A, GCC1, GLIS3, HNF4A, IL6, INS, KCNK15, KCNK16, KCTD12, IDE, LDLR, LOC646279, MAF, MMP26, NXPH1, NGN3, NPC1, PCSK1, PEPD, PRC1, PRL, PROX1, PSMD6, PTER, RALGPS2, RORA, SDCCAG8, ST64GAL1, TMEM18, TNKS, UBQLNL, ZFAND3*

Cross-sectional studies
-----------------------

Among the 46 included studies, 32 studies^[@r18],[@r19],[@r21]--[@r25],[@r27]--[@r33],[@r36],[@r37],[@r39],[@r40],[@r43]--[@r48],[@r50]--[@r54],[@r56],[@r60],[@r61]^ that included 145,162 participants and 57,985 cases used a cross-sectional design. Mean age and BMI ranged from 33.7--68.8 years and from 23.2--36.9 kg/m^2^, respectively. The median proportion of men was 47%. Figure [2](#fig02){ref-type="fig"} shows a forest plot of ORs for T2DM, with a 95% confidence interval (CI), for 1-ΔRA. Overall, the OR for T2DM was highly significant (OR 1.16; 95% CI, 1.13--1.19; *P* \< 0.001). However, there was highly significant between-study heterogeneity in the magnitude of ORs for T2DM (I-squared = 93.6%, *P* \< 0.001). Publication bias was statistically suggested using both Begg's and Egger's tests (*P* = 0.03 and *P* = 0.01, respectively). Adjustment for publication bias using the trim and fill method slightly attenuated the T2DM risk but it remained highly significant (OR 1.15; 95% CI, 1.12--1.18; *P* \< 0.001).

![Forest plot of odds ratio (OR) with 95% confidence interval (CI) for risk of type 2 diabetes mellitus with 95% CI for 1 increment in risk alleles carried in cross-sectional studies. The OR in each study and the overall OR are indicated by squares and a diamond, respectively. Horizontal lines indicate the range of the 95% CI. The area of each square is proportional to the study weight expressed as the inverse of the square of standard error based on a random-effects model.](je-28-003-g002){#fig02}

Table [8](#tbl08){ref-type="table"} shows the results of the stratified analysis of T2DM risk for 1-ΔRA using several pre-specified study characteristics. The OR for 1-ΔRA was consistently significant throughout any strata within individual subheadings. However, studies using 10 or more SNPs for T2DM screening revealed a smaller OR than those using less than 10 SNPs (pooled OR 1.14; 95% CI, 1.11--1.17 vs OR 1.25; 95% CI, 1.19--1.31; *P* = 0.002). The strength of the association was not significantly influenced by whether the OR was adjusted for BMI (*P* = 0.82). A significantly stronger association with T2DM risk was observed in studies of participants having a relatively lower mean BMI (\<27 kg/m^2^ vs ≥27 kg/m^2^; *P* = 0.03) while a significantly weaker association was observed in studies that were women-dominant (*P* = 0.04). A negative association between mean BMI and T2DM risk for 1-ΔRA was also observed by entering the mean BMI as a continuous variable, predicting ORs of 1.18 and 1.11 for mean BMIs of 30 kg/m^2^ and 25 kg/m^2^, respectively. The pooling of studies that were considered to primarily represent Asian ethnicity, which were conducted in Japan, China, India, Singapore, or Pakistan, or targeted for Japanese-Americans, resulted in a significantly larger OR than the pooling of the other studies (*P* = 0.01). Also, excluding studies conducted in Western countries, including the United States, Mexico, Latvia, the United Kingdom, Sweden, Switzerland, France, Canada, or Denmark, resulted in a smaller OR compared with studies conducted in those Western countries (*P* = 0.02). Studies that excluded individuals with IGT from the non-T2DM cases revealed a larger OR compared with studies that did not (*P* = 0.002), while studies that excluded individuals with IFG did not influence the magnitude of the OR. Analysis was not influenced by whether or not OGTT was used for T2DM screening (*P* = 0.17).

###### Stratified meta-analysis of eligible cross-sectional studies by several study items related to study characteristics for the pooled odds ratio (OR) for type 2 diabetes mellitus (DM) per 1 increase in risk alleles carried in relation to single nucleotide polymorphism (SNP)

  Item                                          Number of data      OR (95% CI)         Q statistics   I-squared   *P* value of heterogeneity   Meta-regression \$
  ------------------------------ -------------- ------------------- ------------------- -------------- ----------- ---------------------------- --------------------
  Total                                         40                  1.16 (1.13--1.19)   613.3          93.6%       \<0.001                       
                                                                                                                                                
  Number of SNPs                 \<10           12                  1.25 (1.11--1.31)   37.8           70.9%       \<0.001                       
  ≥10                            28             1.14 (1.11--1.17)   522.1               94.8%          \<0.001     0.002                        
                                                                                                                                                
  Mean age                       \<55 years     16                  1.17 (1.11--1.22)   191.4          92.2%       \<0.001                       
  ≥55 years                      24             1.16 (1.13--1.20)   395.5               94.2%          \<0.001     0.95                         
                                                                                                                                                
  Proportion of men              \<50%          26                  1.14 (1.11--1.17)   361.5          93.1%       \<0.001                       
  ≥50%                           13             1.21 (1.16--1.26)   101.6               88.2%          \<0.001     0.04\#                       
  N/A                            1              1.13 (1.05--1.22)   ---                 ---            ---         ---                          
                                                                                                                                                
  Country                        Western        24                  1.13 (1.10--1.16)   307.0          92.5%       \<0.001                       
  Non-Western                    16             1.20 (1.16--1.25)   213.7               93.0%          \<0.001     0.01                         
                                                                                                                                                
  Dominant ethnic group          Asian          16                  1.20 (1.16--1.25)   233.4          93.6%       \<0.001                       
  Non-Asian                      24             1.13 (1.10--1.16)   273.4               91.6%          \<0.001     0.01                         
                                                                                                                                                
  Mean BMI^\*^                   \<27 kg/m^2^   22                  1.19 (1.15--1.24)   448.4          95.3%       \<0.001                       
  ≥27 kg/m^2^                    18             1.11 (1.09--1.14)   88.3                80.7%          \<0.001     0.03                         
                                                                                                                                                
  Adjustment for BMI             Yes            31                  1.16 (1.13--1.20)   535.5          94.4%       \<0.001                       
  No                             9              1.15 (1.10--1.21)   66                  87.9%          \<0.001     0.82                         
                                                                                                                                                
  Using OGTT to diagnose DM      Yes            14                  1.19 (1.14--1.25)   205.1          93.7%       \<0.001                       
  No                             26             1.15 (1.11--1.18)   389.0               93.6%          \<0.001     0.17                         
                                                                                                                                                
  Excluding IGT from non-cases   Yes            7                   1.28 (1.22--1.34)   15.4           31.0%       0.009                         
  No                             33             1.14 (1.12--1.17)   508.5               93.5%          \<0.001     0.002                        
                                                                                                                                                
  Excluding IFG from non-cases   Yes            13                  1.18 (1.13--1.23)   189.6          93.7%       \<0.001                       
  No                             27             1.15 (1.12--1.19)   406.5               93.6%          \<0.001     0.42                         

BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; OR, odds ratio; SNPs, single nucleotide polymorphisms.

Table [9](#tbl09){ref-type="table"} shows the results of the multivariate meta-regression analysis that simultaneously entered several of the study characteristics used in the stratified analyses as explanatory variables. Consistent with the results of the stratified analyses that were previously described (ie, univariate analyses), studies that had a women-dominant population and were examined in Western countries revealed a smaller OR for T2DM for 1-ΔRA (*P* = 0.005 and *P* = 0.02, respectively) while studies that primarily targeted those of Asian ethnicity revealed a larger OR (*P* = 0.02). Unlike the results of the univariate analysis, neither the mean BMI, country where the individual study was conducted (Western or non-Western), nor the ethnic group (Asian or non-Asian) influenced the magnitude of the OR. However, in the multivariate analysis, the influence of the mean BMI became non-significant.

###### Univariate and multivariate meta-regression analyses of eligible cross-sectional studies for odds ratio for type 2 diabetes mellitus (T2DM) for 1 increment in risk alleles carried in relation to diabetes-associated single nucleotide polymorphisms (SNPs) by characteristics of study design^a^

  Variable                      Univariate^b^ *N* = 40   Multivariate 1 *N* = 39^c^   Multivariate 2 *N* = 39^c^                                                                      
  ----------------------------- ------------------------ ---------------------------- ---------------------------- -------- ---------------- -------------- -------- ---------------- --------------
  No. SNPs ≥10                  −0.094                   0.029                        0.002                        −0.077   0.033            0.03           −0.084   0.033            0.02
  Western country               −0.062                   0.025                        0.02                         −0.060   0.025            0.02           ^e^                        
  Asian ethnicity               0.065                    0.025                        0.01                         ^e^                                      0.081    0.031            0.02
  Mean age ≥55 years            −0.002                   0.028                        0.95                         −0.003   0.021            0.90           −0.019   0.023            0.42
  Women-dominant^c^             −0.061                   0.028                        0.04                         −0.065   0.022            0.005          −0.064   0.022            0.006
  BMI ≥27 kg/m^2^               −0.057                   0.025                        0.03                         −0.005   0.025            0.84           0.018    0.027            0.56
  Adjustment for BMI            0.009                    0.033                        0.79                         0.024    0.028            0.40           0.024    0.028            0.39
  Using OGTT to diagnose DM     0.039                    0.028                        0.17                         −0.004   0.026            0.88           −0.017   0.027            0.53
  Excluding IGT from noncases   0.115                    0.035                        0.002                        0.074    0.046            0.12           0.074    0.046            0.12
  Excluding IFG from noncases   0.023                    0.028                        0.42                         −0.019   0.023            0.42           −0.010   0.023            0.66
                                                                                                                                                                                      
  R-squared                                                                                                                 64.4%                                    61.4%             
  F-test                                                                                                                    F(9,29) = 4.60   *P* \< 0.001            F(9,29) = 4.70   *P* \< 0.001

Abbreviations: Same as in Table [8](#tbl08){ref-type="table"}.

^a^Logarithm of odds ratio for T2DM was a dependent variable, and each study characteristic was entered as an explanatory variable.

^b^Fundamentally, results were consistent with the stratified analysis.

^c^*N* = 39 because one study^[@r54]^ in which the proportion of men was not available was excluded.

^d^Positive value of the coefficient means that the OR is higher when the answer to each variable is "Yes" compared with a "No" answer. The same interpretation of the results is applied to Table [10](#tbl10){ref-type="table"}, Table [12](#tbl12){ref-type="table"}, and Table [13](#tbl13){ref-type="table"}.

^e^Western country and Asian ethnicity was not entered simultaneously because of collinearlity.

Table [10](#tbl10){ref-type="table"} shows the results of univariate and multivariate meta-regression analyses according to whether each of the top 10 previously mentioned genes were used or not. In both univariate and multivariate analyses, the FTO gene was associated with a lower OR for T2DM. In the multivariate analysis, the 10 genes explained 59.9% of the variance in the log OR (*P* = 0.04).

###### Univariate and multivariate meta-regression analyses of eligible cross-sectional studies for odds ratio for type 2 diabetes mellitus (T2DM) for 1 increment in risk alleles carried in relation to diabetes-associated single nucleotide polymorphisms (SNPs) by whether or not each of the top 10 of commonly used genes in this meta-analysis was examined^a^

  Genes       Univariate *N* = 40   Multivariate *N* = 40                                       
  ----------- --------------------- ----------------------- --------- -------- ---------------- ------------
  *CDKAL1*    −0.073                0.033                   0.03      −0.061   0.069            0.38
  *TCF7L2*    −0.016                0.031                   0.60      0.015    0.035            0.65
  *CDKN*      −0.073                0.033                   0.03      ^b^                        
  *HHEX*      −0.067                0.029                   0.03      −0.025   0.056            0.65
  *IGFBP2*    −0.061                0.029                   0.04      0.010    0.052            0.84
  *SLC30A8*   −0.029                0.029                   0.03      0.026    0.047            0.58
  *KCNJ11*    −0.004                0.027                   0.89      0.008    0.033            0.81
  *PPARγ*     −0.030                0.027                   0.28      −0.025   0.037            0.51
  *FTO*       −0.101                0.021                   \<0.001   −0.087   0.027            0.003
  *KCNQ1*     −0.037                0.028                   0.20      0.011    0.041            0.08
                                                                                                
  R-squared                                                                    59.9%             
   F-test                                                                      F(9,30) = 2.39   *P* = 0.04

SE, standard error.

^a^Logarithm of odds ratio for diabetes mellitus was a dependent variable, and each study characteristic was entered as an explanatory variable.

^b^*CDKN* could not be entered simultaneously because of collinearlity.

Longitudinal studies
--------------------

Included were 15 longitudinal studies^[@r17],[@r20],[@r26],[@r34],[@r35],[@r38],[@r41],[@r42],[@r48],[@r49],[@r55],[@r57]--[@r59],[@r62]^ comprised of 104,203 participants, among which 17,666 participants developed T2DM. Figure [3](#fig03){ref-type="fig"} shows a forest plot of ORs of T2DM with 95% CI of T2DM for 1-ΔRA. The pooled OR for 1-ΔRA was 1.10 (95% CI, 1.08--1.13), which was significantly smaller than when cross-sectional studies were pooled (*P* = 0.04). Publication bias was detected using Egger's test (*P* = 0.04) but not using Begg's test (*P* = 0.40). However, the adjustment for publication bias resulted in no change in the overall estimate.

![Forest plot of odds ratio (OR) with 95% confidence interval (CI) for risk of type 2 diabetes mellitus with 95% CI for 1 increment in risk alleles carried in longitudinal studies. The OR in each study and the overall OR are indicated in squares and a diamond, respectively. Horizontal lines indicate the range of the 95% CI. The area of each square is proportional to the study weight expressed as the inverse of the square of standard error based on a random-effects model.](je-28-003-g003){#fig03}

Two studies^[@r26],[@r62]^ targeted exclusively IGT participants, while the other studies did not specify participants at high risk of T2DM according to IGT values. However, after excluding those studies, the overall OR was not influenced (OR 1.11; 95% CI, 1.08--1.14; *P* = 0.70). In the results of stratified and multivariate meta-regression analyses using several study characteristics, no variables that influenced T2DM risk could be detected, partly because these sensitivity analyses had insufficient statistical power due to the small number of datasets (Table [11](#tbl11){ref-type="table"} and Table [12](#tbl12){ref-type="table"}). Nevertheless, studies using ≥10 SNPs revealed a smaller OR than those using \<10 SNPs in the stratified analysis (pooled OR 1.10; 95% CI, 1.07--1.12 vs OR 1.34; 95% CI, 1.21--1.49; *P* = 0.005) (Table [11](#tbl11){ref-type="table"}). Studies using 10 or more SNPs for T2DM screening revealed smaller ORs than those using less than 10 SNPs. Table [13](#tbl13){ref-type="table"} shows results of univariate and multivariate meta-regression analyses indicating whether each of the top commonly used genes was used for prediction of T2DM. Although none of the 10 genes significantly influenced the log OR of T2DM risk in both univariate and multivariate meta-regression analyses, multivariate analysis indicated that 67.5% of the variance in the log OR could be explained by whether or not each of the 10 genes was used (*P* = 0.006).

###### Stratified meta-analysis of eligible longitudinal studies by several study items related to study characteristics for pooled odds ratio (OR) of type 2 diabetes mellitus (DM) per 1 increment in risk alleles carried in relation to single nucleotide polymorphism (SNP)

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Item                                       Number of\          OR (95% CI)         Q statistics   I-squared   *P* value of\   Meta-regression^d^
                                             data                                                               heterogeneity   
  --------------------------- -------------- ------------------- ------------------- -------------- ----------- --------------- --------------------
  Total                                      21                  1.10 (1.08--1.13)   94.5           78.8%       \<0.001          

                                                                                                                                

  Number of SNPs              \<10           4                   1.34 (1.21--1.49)   4.6            35.2%       0.20             

  ≥10                         17             1.10 (1.07--1.12)   74.8                78.6%          \<0.001     0.005           

                                                                                                                                

  Mean age^b^                 \<50 years     9                   1.11 (1.06--1.14)   28.6           72.0%       \<0.001          

  ≥50 years                   11             1.11 (1.07--1.15)   60.2                83.4%          \<0.001     0.95            

                                                                                                                                

  Proportion of men           \<50%          15                  1.09 (1.06--1.12)   65.3           78.6%       \<0.001          

  ≥50%                        6              1.14 (1.09--1.20)   21.3                76.6%          0.00        0.19            

                                                                                                                                

  Country                     Western        19                  1.10 (1.08--1.13)   91.1           80.2%       \<0.001          

  Non-Western                 2              1.16 (1.05--1.29)   2.1                 51.3%          0.15        0.40            

                                                                                                                                

  Dominant ethnic Group       White          15                  1.10 (1.08--1.13)   89.3           83.2%       \<0.001          

  Non-White                   5              1.10 (1.06--1.13)   5.2                 23.1%          0.27        0.94            

                                                                                                                                

  Mean BMI^a,b,c^             \<25 kg/m^2^   7                   1.12 (1.08--1.17)   15.6           61.5%       0.02             

  ≥25 kg/m^2^                 13             1.10 (1.07--1.13)   75.8                84.2%          \<0.001     0.5             

                                                                                                                                

  Adjustment for BMI          Yes            17                  1.10 (1.08--1.13)   63.0           74.6%       \<0.001          

  No                          4              1.10 (1.05--1.16)   18.5                83.8%          \<0.001     0.96            

                                                                                                                                

  Using OGTT to diagnose DM   Yes            12                  1.11 (1.07--1.15)   41.5           73.5%       \<0.001          

  No                          9              1.10 (1.06--1.13)   45.1                82.3%          \<0.001     0.80            
  --------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance; N/A, not applicable.

^a^Indicates mean BMI of study population at recruitment.

^b^One study^[@r17]^ did not present data on mean age or BMI.

^c^Indicates mean BMI at the beginning of follow-up.

^d^*P* value for difference in the magnitude of logarithm of odds ratio between strata was indicated.

###### Univariate and multivariate meta-regression analysis of eligible longitudinal studies for odds ratio of type 2 diabetes mellitus for 1 increment in risk alleles in relation to diabetes-associated single nucleotide polymorphism (SNP)^a^ according to characteristics of study design^a^

  Variable                         Univariate^c^ *N* = 21   Multivariate 1 *N* = 20^b^   Multivariate 2 *N* = 20^b^                                                                    
  -------------------------------- ------------------------ ---------------------------- ---------------------------- -------- ---------------- ------------ -------- ---------------- ------------
  Number of SNPs ≥10 (Yes/No)      −0.206                   0.066                        0.005                        −0.182   0.083            0.049        −0.186   0.082            0.04
  Western country (Yes/No)         −0.067                   0.078                        0.40                         −0.035   0.091            0.7          ^d^                        
  White-dominant (Yes/No)          −0.003                   0.039                        0.94                         ^d^                                    0.002    0.04             0.97
  Mean age ≥50 years (Yes/No)^b^   0.002                    0.034                        0.95                         0.01     0.04             0.82         0.017    0.037            0.67
  Women-dominant                   −0.045                   0.033                        0.19                         −0.052   0.042            0.24         −0.049   0.042            0.27
  BMI ≥25 kg/m^2^ (Yes/No)         −0.025                   0.036                        0.50                         0.01     0.048            0.84         0.000    0.043            1.00
  Adjustment for BMI               0.002                    0.038                        0.96                         −0.011   0.04             0.79         −0.007   0.042            0.88
  Using OGTT to diagnose DM        0.008                    0.032                        0.80                         −0.006   0.035            0.87         −0.004   0.035            0.91
                                                                                                                                                                                       
  R-squared                                                                                                                    49.1%                                  47.5%             
  F-test                                                                                                                       F(7,12) = 1.39   *P* = 0.29            F(7,12) = 1.37   *P* = 0.30

BMI, body mass index; DM, diabetes mellitus; OGTT, oral glucose tolerance test; SE, standard error.

^a^Logarithm of odds ratio for diabetes mellitus was a dependent variable, and each study characteristic was entered as an explanatory variable.

^b^*N* = 20 because one study^[@r17]^ did not present data on mean age or BMI.

^c^Fundamentally, the results were consistent with the stratified analysis.

^d^Western country and Asian ethnicity was not entered simultaneously because of collinearlity.

###### Univariate and multivariate meta-regression analyses of eligible longitudinal studies for odds ratio for type 2 diabetes mellitus (T2DM) for 1 increment in risk alleles carried in relation to diabetes-associated single nucleotide polymorphisms (SNPs) by whether or not each of the top 10 of the commonly used genes in this meta-analysis was examined^a^

  Genes       Univariate *N* = 21   Multivariate *N* = 21                                    
  ----------- --------------------- ----------------------- ------ -------- ---------------- -------------
  *CDKAL1*    −0.031                0.055                   0.58   ^b^                        
  *TCF7L2*    0.011                 0.058                   0.86   0.261    0.096            0.02
  *CDKN*      −0.024                0.044                   0.58   0.044    0.030            0.17
  *HHEX*      −0.057                0.051                   0.28   −0.486   0.190            0.02
  *IGFBP2*    −0.057                0.051                   0.28   ^b^                        
  *SLC30A8*   −0.031                0.055                   0.58   0.292    0.163            0.10
  *KCNJ11*    −0.057                0.051                   0.28   ^b^                        
  *PPARγ*     −0.057                0.051                   0.28   ^b^                        
  *FTO*       −0.057                0.03                    0.08   0.014    0.022            0.59
  *KCNQ1*     −0.042                0.028                   0.16   −0.074   0.022            0.004
                                                                                             
  R-squared                                                                 67.5%             
   F-test                                                                   F(6,14) = 5.09   *P* = 0.006

SE, standard error.

^a^Logarithm of odds ratio for diabetes mellitus was a dependent variable, and each study characteristic was entered as an explanatory variable.

^b^The 4 genes could not be entered simultaneously because of collinearlity.

DISCUSSION
==========

The current meta-analysis indicated that 1-ΔRA in T2DM-associated SNPs was associated with a modest risk of prevalent or incident T2DM. A previous meta-analysis^[@r06]^ indicated that the pooled RR of incident T2DM was 1.87 for an increment of 4.3 kg/m^2^ in the BMI. If the magnitude of T2DM risk is compared between 1-ΔRA and 1-ΔBMI, 1-ΔRA corresponds to only 0.58-ΔBMI (Δ1.7 kg, if body height is 1.7 meters), assuming that the cumulative incidence rate of T2DM in the referent is p~0~ = 10% and the OR is transformed into an RR using the following formula: $\text{RR} = \frac{\text{OR}}{(1 - \text{p}_{0}) + \text{p}_{0} \times \text{OR}}$.^[@r08]^ This estimation was made by the following calculations:$$\begin{array}{l}
{\frac{1.10}{(1 - 0.1) + 0.1 \times 1.10} = 1.089} \\
{\text{log}(1.089) = 0.085} \\
{\frac{\text{log}(1.87)}{4.3} = 0.146} \\
{\frac{0.085}{0.146} = 0.58} \\
\end{array}$$In other words, having 1 RA was equivalent to losing less than 2 kg body weight.

Assuming the monotonicity between the number of RAs carried and T2DM risk, the magnitude of disease risk will endlessly expand with increases in the RAs carried, even if the effect size of each SNP is modest. Therefore, GWAS may be able to detect individuals at extremely high risk of T2DM if the number of the identified T2DM-associated SNPs is progressively increased. However, the magnitude of T2DM risk might reach a plateau, which was suggested from the result of the stratified analysis that indicated that studies using a larger number of SNPs (10 or more) revealed a smaller OR of T2DM for 1-ΔRA compared with those using a smaller number of SNPs. Although the observed higher risk when using a smaller number of genes could be spurious due to the winner's curse effect (eg, T2DM risk would be higher when using only the top two genes that were strongly associated with susceptibility to T2DM than when using the top 10 genes), this result reflects the fact that the T2DM-susceptible loci were detected in order of descending effect size related to T2DM risk among all proposed loci.^[@r65]^ Of note, although the magnitude of genetic T2DM risk was modest, this did not mean that the risk was ignorable from the result of the stratified analysis that indicated that the association of cumulative RAs with T2DM risk was not weakened after adjusting the T2DM risk for BMI. This result suggested that the genetic T2DM risk existed independently of obesity, which is well known as one of the greatest risk factors for T2DM.

The current meta-analysis indicated a large heterogeneity in the magnitude of the T2DM risk for cumulative RAs, which was in a large part explained by the choice of the T2DM-susceptible genes. This suggested that the magnitude of T2DM risk depended on what genes were used. In particular, the cross-sectional studies that used the *FTO* gene revealed a lower OR compared with those that did not use it, which suggested that it is unnecessary to examine the *FTO* gene if clinical risk factors for T2DM were simultaneously assessed. *FTO* is one of the most well-known of the obesity-associated genes.^[@r66]^ Considering that the OR for T2DM was adjusted for obesity in most of the studies included in this meta-analysis, the T2DM risk associated with the *FTO* gene could have been masked by that associated with obesity. Although the magnitude of T2DM risk was not influenced by whether or not *FTO* was used in the longitudinal studies, the inconsistency in the results between the meta-analysis of cross-sectional studies and that of longitudinal studies could be explained by differences in the exposure to risk factors (ie, participants in longitudinal studies were recruited before they became obese, although those in cross-sectional studies had already become obese at recruitment). Despite the heterogeneity in the choice of the T2DM-susceptible genes, the forest plots shown in Figure [2](#fig02){ref-type="fig"} and Figure [3](#fig03){ref-type="fig"} indicate that the OR for carrying 1-ΔRA was within 1.0--1.3. This value corresponds to a modest effect size.^[@r04]^ Therefore, it is unlikely that heterogeneity in the genes among studies changed the main conclusion of this study. Nevertheless, the heterogeneity in the magnitude of T2DM risk due to the heterogeneity among the used genes urges us interpret the results with caution.

The current stratified meta-analysis of cross-sectional studies indicated that a larger magnitude of T2DM risk in relation to cumulative RAs was observed in studies with a proportion of men 50% or greater compared with women-dominant studies, suggesting that the magnitude of the genetic association with T2DM was larger in men than in women. Although evidence for gender-related differences in genetic associations has been insufficient,^[@r67]^ some major longitudinal studies suggested that the environmental contribution to T2DM risk differed by gender. For example, regarding moderate physical activity, which has been established to reduce T2DM risk,^[@r68]^ the MONICA/KORA Augsburg Cohort study suggested that leisure time physical activity was effective in preventing T2DM, especially in women.^[@r69]^ In the intensive lifestyle modification group in the Diabetes Prevention Program, the effect in preventing incident T2DM did not differ by sex, although men lost significantly more body weight and increased physical activity more than did women.^[@r70]^ The relative contribution of genetic risk to incident T2DM could be smaller in women than in men. Further studies would need to analyze the T2DM risk in relation to genetic risk by gender to clarify the gender difference in the relative contribution of genetic profiles. Of note, this suggestion was contradictory to the finding in one of the included studies in this meta-analysis, which indicated that carrying RAs was associated with T2DM in women but not in men.^[@r62]^ However, this study focused on *ADIPOQ* among the established T2DM-susceptible genes and limited the subjects to those who already had IGT at cohort entry. *ADIPOQ* might play a role in the determination of the severity of glucose tolerance, especially in women, although the majority of SNPs used for T2DM screening was associated with discrimination of glucose intolerance from normal glucose tolerance.

Current sensitivity analyses indicated that there was a stronger association between cumulative RAs and T2DM risk in study populations with lower mean BMI. This finding was supported by previous studies that stratified the analyses by BMI, although these data could not be included in this meta-analysis because characteristics other than BMI in each subgroup were not presented.^[@r20],[@r25]^ However, ethnicity or geographic region, rather than obesity, might affect the strength of the association between cumulative RAs and T2DM risk, considering that the prevalence of overweight and obesity in Asia is relatively low compared with Western populations.^[@r71]^ To our knowledge, no studies have investigated the difference in the magnitude of T2DM risk by ethnicity using two or more SNPs, although a difference in the attributable risk of a certain T2DM-susceptible SNP has been suggested.^[@r72]^ Whether an included study was targeted on an Asian-dominant ethnicity or whether it was conducted in Western countries affected the magnitude of T2DM risk for an increment in the number of RAs carried in both univariate and multivariate meta-regression analyses. However, modification of the magnitude of T2DM risk by the mean BMI that was shown in univariate analyses disappeared in the multivariate analyses. It could be interpreted that the contribution of genes to T2DM risk could be affected by ethnicity rather than physical background. Unfortunately, when applied to the included studies in the current meta-analysis, this hypothesis was directly elucidated by only one study, which compared the magnitude of T2DM risk between Asian and non-Asian ethnic groups.^[@r47]^ Further studies are needed to confirm the characteristics of individuals or populations that are susceptible to genetic T2DM risk, including determinations of whether the characteristic was the extent of obesity or ethnicity.

The result of the current stratified meta-analyses might reflect characteristics regarding metabolic traits of persons at high genetic risk of T2DM: a higher OR was observed in studies that excluded subjects without T2DM who had IGT compared with studies that did not exclude subjects with IGT, but no difference in ORs was observed according to whether or not subjects with IFG were excluded, which meant that inclusion of subjects with IGT in the non-case group weakened the association between cumulative RA and T2DM risk. A previous study reported that the genetic risk score was reported to be cross-sectionally associated with the risk of having IGT but not IFG using nine genes (*FTO, HHEX, KCNJ11, KCNQ1, MTNR1B, PPARG, SLC30A8, TCF7L2, WFS1*), which were established to be major loci associated with the risk of T2DM.^[@r73]^ When applying this finding to this meta-analysis, seven of these nine genes were ranked in the top 10 genes that frequently appeared in the included studies in this meta-analysis. Major T2DM-associated genes that were discovered in the current GWAS might have a stronger association with glucose intolerance than T2DM itself. Considering that T2DM is a partly a result of progression of glucose intolerance, incident T2DM could be prevented by non-genetic factors, although mild glucose tolerance was inevitably regulated by genes. This suggestion was supported by evidence for the benefit of lifestyle interventions in reducing the risk of progression from IGT to T2DM.^[@r74]^

Several limitations should be addressed. First, this meta-analysis had to assume the log-linearity between the number of RAs carried and the observed T2DM risk. Second, this meta-analysis assumed that each SNP within one study would equally contribute to the risk of T2DM, although the OR for each SNP varied. However, it was reported that the difference in the discriminative power between using an unweighted and weighted genetic risk score was not significant^[@r43]^ or was modest.^[@r51]^ Third, as previously mentioned, the genes that were used in the examination of the association with prevalence and incidence of T2DM were too heterogeneous to analyze by the combination of the used genes. Nevertheless, the genes used for genetic risk should be the same across the studies. Fourth, this meta-analysis also did not consider heterogeneity in covariates for which each study adjusted T2DM risk. To minimize this heterogeneity, analyses were limited to the ORs that were adjusted for at least two of three covariates: age, gender, and BMI. In addition, sensitivity analyses confirmed that the magnitude of T2DM risk was not influenced by whether these ORs were adjusted for BMI. Therefore, the current meta-analysis could confirm that the genetic T2DM risk was independent of age, gender, and obesity. Although these are well known to be major classic risk factors for T2DM, it needs to be emphasized that other residual confounders could not be ruled out.

Conclusions
-----------

The current meta-analysis indicated that carrying one RA in T2DM-associated SNPs was associated with a modest risk of prevalent or incident T2DM as far as the SNPs discovered in GWAS were concerned, although the heterogeneity in the genes examined among studies indicates that we should interpret the results with caution.
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